The invention relates to a solid deep eutectic solvent (solid DES) that is solid at 20° C., comprising a salt of an active pharmaceutical ingredient, the method to obtain the solid deep eutectic solvent and the use of the deep eutectic solvent for medical treatment. The solid deep eutectic solvent is obtained by at least partially removing a plasticizer from a first DES.

Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of a disease or disorder, e.g., autoimmune disease, inflammatory disease, central nervous system disorder, cardiovascular disease, or metabolic disorder. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.

The present invention relates to a pharmaceutical composition comprising an inclusion complex of amorphous lenalidomide, or a pharmaceutically acceptable salt thereof, in non-substituted β-cyclodextrin and one or more pharmaceutically acceptable excipients. The invention further relates to the use of said composition as a medicament, particularly in the treatment of in the treatment of multiple myeloma and myelodyplastic syndromes.

The present invention provides a polyrotaxane which exhibits more excellent compatibility with various solvents, while having good processability. The present invention provides a polyrotaxane which is obtained by arranging blocking groups on both ends of a pseudopolyrotaxane, wherein a linear molecule passes through the opening of a circular molecule in a skewering manner, for the purpose of preventing elimination of the circular molecule. This polyrotaxane has a group which has a chain that is formed by having the circular molecule have a propyleneoxy repeating unit; and this polyrotaxane is soluble in a polyalkyleneoxy polyol, which has a number average molecular weight of 1,000 or more, at room temperature.

The present invention provides a method for producing an aqueous dispersion of pseudopolyrotaxane that enables the production, by an industrially advantageous method for an aqueous dispersion of pseudopolyrotaxane in which the inclusion amount of a cyclodextrin does not increase with time and which can provide a crosslinked polyrotaxane having sufficient stretchability and breaking strength. The present invention relates to a method for producing an aqueous dispersion of pseudopolyrotaxane containing pseudopolyrotaxane particles in which a polyethylene glycol is included in a cavity of a cyclodextrin molecule in a skewered manner, the method including: an inclusion step of mixing a polyethylene glycol and a cyclodextrin in an aqueous medium to include the polyethylene glycol in a cavity of a cyclodextrin molecule, wherein in the inclusion step, a basic compound is added.

Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.

This document relates to shape memory compositions containing a sliding-ring polymer (polyrotaxane) additive and a thermally-curable epoxy resin. The shape memory compositions are able to deform and reform in response to external stimuli. This document also relates to 3D-printed shape memory compositions containing a sliding-ring polymer (polyrotaxane) additive and a thermally-curable epoxy resin.

This application discloses a caffeinated drink with cannabinoids, wherein the drink retains its original taste and appearance. This application also discloses coffee powder with cannabinoids, roasted coffee beans with cannabinoids, and loose tea leaf with cannabinoids. Methods to the make and use of the above caffeinated drinks, coffee powder, coffee beans, and loose tea leaf are also disclosed.

An object of the present invention is to provide a golf ball showing improved controllability on approach shots for less than 40 yards, in particular, on approach shots around the green (about 10 yards to 20 yards) and improved controllability on approach shots from the rough, and showing excellent shot feeling. The present invention provides a golf ball comprising a golf ball body and a paint film covering the golf ball body, wherein a loss tangent tan δ has a peak temperature of 50° C. or less and a peak height of less than 0.8, obtained by measuring dynamic viscoelasticity of the paint film under the following conditions: <Measuring conditions> Measuring mode: tensile mode Measuring temperature range: from −100° C. to 150° C. Temperature rising rate: 4° C./min Oscillation frequency: 10 Hz Measuring strain: 0.1%.

An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.